Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

101761

registered interest
date	30/10/2014
answering body	Department for Business, Innovation and Skills
answering dept id	26
answering dept short name	Business, Innovation and Skills
answering dept sort name	Business, Innovation and Skills
hansard heading	Biotechnology
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Business, Innovation and Skills, what estimate he has made of the number of jobs in each region and constituent part of the UK which are supported by the life science industry.
tabling member constituency	Salisbury
tabling member printed	John Glen
uin	212639
answer	answer is ministerial correction date of answer 07/11/2014 answer text <p>There are no published official statistics on the regional distribution of life science industry jobs. The table below includes an estimate of employment in 2013 in companies active in three “health life science” sectors: Medical Biotechnology, Medical Technology and Pharmaceuticals, by region and by constituent part of the UK, obtained from the Bioscience and Health Technology company database used by the Office for Life Sciences. The figures are based on locations of active sites for which employment figures can be obtained. They do not include those employed by public or third sector organisations nor employment in companies whose main activity falls outside life sciences, including indirect suppliers to the sector.</p><p> </p><table><tbody><tr><td> </td><td><p><strong>Number of employees in health life science industry ‘000s 2013</strong></p></td></tr><tr><td><p>East Midlands</p></td><td><p>9.5</p></td></tr><tr><td><p>East of England</p></td><td><p>28.8</p></td></tr><tr><td><p>Greater London</p></td><td><p>13.6</p></td></tr><tr><td><p>North East England</p></td><td><p>7.1</p></td></tr><tr><td><p>North West England</p></td><td><p>17.0</p></td></tr><tr><td><p>South East England</p></td><td><p>36.8</p></td></tr><tr><td><p>South West England</p></td><td><p>8.2</p></td></tr><tr><td><p>West Midlands</p></td><td><p>14.5</p></td></tr><tr><td><p>Yorkshire and the Humber</p></td><td><p>13.5</p></td></tr><tr><td><p>England total</p></td><td><p>149.0</p></td></tr><tr><td> </td><td> </td></tr><tr><td><p>Northern Ireland</p></td><td><p>4.3</p></td></tr><tr><td><p>Scotland</p></td><td><p>11.5</p></td></tr><tr><td><p>Wales</p></td><td><p>9.1</p></td></tr><tr><td><p>UK Total</p></td><td><p>173.9</p></td></tr></tbody></table><p>Source: Bioscience and Health Technology database, an annual summary of the data was published as “Strength and Opportunity 2013, the landscape of the medical technology, medical biotechnology, industrial biotechnology and pharmaceutical sectors in the UK”</p><p> </p><p> </p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 07/11/2014 16:53:00 answering member 4020 label Biography information for George Freeman
tabling member	4051 label Biography information for John Glen

101774

registered interest
date	30/10/2014
answering body	Department for Business, Innovation and Skills
answering dept id	26
answering dept short name	Business, Innovation and Skills
answering dept sort name	Business, Innovation and Skills
hansard heading	Biotechnology
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Business, Innovation and Skills, what comparative assessment he has made of the competitiveness of the (a) UK, (b) France, (c) Germany, (d) China and (e) US life science industry.
tabling member constituency	Salisbury
tabling member printed	John Glen
uin	212635
answer	answer is ministerial correction date of answer 11/11/2014 answer text <p>The UK pharmaceutical sector contributes more than £13 billion to UK Gross Value Added (GVA), making it the second largest in Europe after Germany measured by GVA. The life sciences sector employs 173,900 people in the UK, and the UK is second only to the US measured by the share of top 1% citations in life science related subjects. The Office of Life Sciences is currently developing a set of indicators reflecting the broad competitiveness of the UK life science environment against key international comparators.</p><p> </p><p>More broadly, the most recent Global Competitiveness Report by the World Economic Forum (WEF) overall ranks the UK within the top 10 competitive countries in which to conduct business, continuing its historical strong performance. The UK is well regarded for its high quality science and research base, high-level skills, openness to international trade and effectiveness of its regulatory and competition regimes and flexible labour market. As a result the UK overall remains a magnet for inward investment, second only to the USA.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 11/11/2014 12:46:09 answering member 4020 label Biography information for George Freeman
tabling member	4051 label Biography information for John Glen

101775

registered interest
date	30/10/2014
answering body	Department for Business, Innovation and Skills
answering dept id	26
answering dept short name	Business, Innovation and Skills
answering dept sort name	Business, Innovation and Skills
hansard heading	Biotechnology
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Business, Innovation and Skills, what structures his Department has in place to ensure that (a) the Life Sciences Organisation and (b) the Office for Life Sciences co-ordinate with the MHRA and National Institute of Health and Care Excellence.
tabling member constituency	Salisbury
tabling member printed	John Glen
uin	212636
answer	answer is ministerial correction date of answer 11/11/2014 answer text <p>Since April 2014 the Office for Life Sciences (OLS) has operated as a joint Director-led unit between the Department of Business Innovation and Skills and the Department of Health. The previous good working relationships between the OLS and MHRA and NICE have been strengthened through this move, as all these bodies are now either part of or sponsored by the Department of Health and all three fall within my Ministerial portfolio.</p><p> </p><p>The UKTI Life Sciences Organisation (LSO) also has strong working relationships with MHRA and NICE, both directly and through the OLS, largely operating on an informal basis rather than within particular structures.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 11/11/2014 11:48:16 answering member 4020 label Biography information for George Freeman
tabling member	4051 label Biography information for John Glen

101878

registered interest
date	30/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Abortion
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how much has been spent on RU486 in each year since January 2011.
tabling member constituency	Romford
tabling member printed	Andrew Rosindell
uin	212552
answer	answer is ministerial correction date of answer 06/11/2014 answer text <p>Information on the net ingredient cost of mifepristone (RU486) used in National Health Service secondary care in England is shown in the table. This may include use in private wards in NHS hospitals and excludes use in military or private hospitals. Mifepristone is not used in primary care.</p><p> </p><p> </p><p> </p><table><tbody><tr><td colspan="2"><p>Net ingredient cost of mifepristone in secondary care, England</p></td></tr><tr><td><p> </p><p>Year</p></td><td><p>Net ingredient cost <br> £000s</p></td></tr><tr><td><p>2013</p></td><td><p>1,107.8</p></td></tr><tr><td><p>2012</p></td><td><p>1,113.6</p></td></tr><tr><td><p>2011</p></td><td><p>1,153.4</p></td></tr></tbody></table><p> </p><p><em>Source:</em> Hospital Pharmacy Audit Index (HPAI) provided by IMS Health</p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 06/11/2014 13:27:01 answering member 4020 label Biography information for George Freeman
tabling member	1447 label Biography information for Andrew Rosindell

101563

registered interest
date	29/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Drugs: Scotland
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment he has made of the effectiveness and merits of (a) the recently announced New Medicines Fund in Scotland and (b) other funding models aimed at driving improved patient access to innovative medicines in the context of the payments made by the pharmaceutical industry under the current Pharmaceutical Pricing Regulation Scheme.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	212458
answer	answer is ministerial correction date of answer 05/11/2014 answer text <p>The New Medicines Fund in Scotland is a matter for the Scottish Government and it would not be appropriate for the Government to comment on its effectiveness or merits.</p><p> </p><p> </p><p> </p><p>In England, in accordance with normal government accounting rules and the agreed 2014 Pharmaceutical Price Regulation Scheme (PPRS), there is no separately identified or ring-fenced funding stream associated with PPRS payments. Nevertheless, the Government can provide an assurance that all PPRS payments received for England will be used for spending on improving patients’ health and care. As part of this, NHS England and the Association of the British Pharmaceutical Industry are pressing ahead with plans to improve access to and optimise the use of medicines to improve patient outcomes.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 05/11/2014 15:04:30 answering member 4020 label Biography information for George Freeman
tabling member	1538 label Biography information for Rosie Cooper

101565

registered interest
date	29/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pharmaceutical Price Regulation Scheme
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, if he will take steps to ensure that payments made by the pharmaceutical industry under the current Pharmaceutical Price Regulation Scheme are used to NHS England to achieve measurable and improved access to new medicines by NHS patients.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	212418
answer	answer is ministerial correction date of answer 04/11/2014 answer text <p>The 2014 Pharmaceutical Price Regulation Scheme (PPRS) supports the National Health Service to improve patient access to clinically and cost effective medicines in a number of ways:</p><p> </p><p> </p><p> </p><p>- by making medicines more affordable. The PPRS limits growth in the vast majority of spend on branded medicines with industry making payments for spend above the agreed limit;</p><p> </p><p> </p><p> </p><p>- by providing stability and predictability to the Government and the pharmaceutical industry thereby promoting a strong and profitable pharmaceutical industry which encourages innovation and the development of high value treatments; and</p><p> </p><p> </p><p> </p><p>- by a number of agreed measure to improve access to branded medicines commensurate with the outcomes they offer patients.</p><p> </p><p> </p><p> </p><p>Sales of new products are exempt from PPRS payments though still included in the overall limit on growth and the payments made by industry as a whole. This creates a strong in-built incentive in the scheme for companies to innovate.</p><p> </p><p><br> In respect of England, the anticipated PPRS payments for 2014-15 were passed on to NHS England through the Mandate and as such were included within commissioner allocations. In addition, an indicative budget for NHS England for 2015-16 was set on the basis of, amongst other things, the PPRS payment forecast available in 2014. <br> <br> In accordance with normal Government accounting rules and the agreed PPRS, there is no separately identified or ring-fenced funding stream associated with PPRS payments. Nevertheless, the Government can provide an assurance that all PPRS payments received for England will be used for spending on improving patients’ health and care. As part of this, following discussion with the Department, NHS England and the Association of the British Pharmaceutical Industry are now pressing ahead with plans to improve access to and optimise the use of medicines to improve patient outcomes.</p><p> </p><p> </p><p> </p><p>More generally, the Government’s <em>Strategy for UK Life Sciences</em> sets out an ambitious long-term programme of action to improve the wider environment for pharmaceutical innovation and make the United Kingdom a world-leading place for life sciences investment. The Strategy has delivered £2 billion in industry and private sector investment in the United Kingdom since it was launched in December 2011.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 212417 212419 question first answered 04/11/2014 17:36:41 answering member 4020 label Biography information for George Freeman previous answer version 25830 answering member constituency Mid Norfolk answering member printed George Freeman answering member 4020 label Biography information for George Freeman
tabling member	1538 label Biography information for Rosie Cooper

101566

registered interest
date	29/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Research
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what plans he has to increase his Department's budget for research and development.
tabling member constituency	Cambridge
tabling member printed	Dr Julian Huppert
uin	212377
answer	answer is ministerial correction date of answer 03/11/2014 answer text <p>Planned expenditure from the research and development budget in 2014-15 is £1,077 million, which in cash terms, represents an increase of 26% in comparison with spend in 2009-10.</p><p> </p><p> </p><p> </p><p>A budget figure for 2015-16 has not yet been set. This will happen as part of standard business planning later this year.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 03/11/2014 17:35:58 answering member 4020 label Biography information for George Freeman
tabling member	3931 label Biography information for Dr Julian Huppert

101575

registered interest
date	29/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pharmaceutical Price Regulation Scheme
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what discussions (a) he and (b) officials in his Department have had on ensuring that the payments made by the pharmaceutical industry under the current Pharmaceutical Price Regulation Scheme will be used to improve access to innovative medicines.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	212417
answer	answer is ministerial correction date of answer 04/11/2014 answer text <p>The 2014 Pharmaceutical Price Regulation Scheme (PPRS) supports the National Health Service to improve patient access to clinically and cost effective medicines in a number of ways:</p><p> </p><p> </p><p> </p><p>- by making medicines more affordable. The PPRS limits growth in the vast majority of spend on branded medicines with industry making payments for spend above the agreed limit;</p><p> </p><p> </p><p> </p><p>- by providing stability and predictability to the Government and the pharmaceutical industry thereby promoting a strong and profitable pharmaceutical industry which encourages innovation and the development of high value treatments; and</p><p> </p><p> </p><p> </p><p>- by a number of agreed measure to improve access to branded medicines commensurate with the outcomes they offer patients.</p><p> </p><p> </p><p> </p><p>Sales of new products are exempt from PPRS payments though still included in the overall limit on growth and the payments made by industry as a whole. This creates a strong in-built incentive in the scheme for companies to innovate.</p><p> </p><p><br> In respect of England, the anticipated PPRS payments for 2014-15 were passed on to NHS England through the Mandate and as such were included within commissioner allocations. In addition, an indicative budget for NHS England for 2015-16 was set on the basis of, amongst other things, the PPRS payment forecast available in 2014. <br> <br> In accordance with normal Government accounting rules and the agreed PPRS, there is no separately identified or ring-fenced funding stream associated with PPRS payments. Nevertheless, the Government can provide an assurance that all PPRS payments received for England will be used for spending on improving patients’ health and care. As part of this, following discussion with the Department, NHS England and the Association of the British Pharmaceutical Industry are now pressing ahead with plans to improve access to and optimise the use of medicines to improve patient outcomes.</p><p> </p><p> </p><p> </p><p>More generally, the Government’s <em>Strategy for UK Life Sciences</em> sets out an ambitious long-term programme of action to improve the wider environment for pharmaceutical innovation and make the United Kingdom a world-leading place for life sciences investment. The Strategy has delivered £2 billion in industry and private sector investment in the United Kingdom since it was launched in December 2011.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 212418 212419 question first answered 04/11/2014 17:36:41 answering member 4020 label Biography information for George Freeman previous answer version 25828 answering member constituency Mid Norfolk answering member printed George Freeman answering member 4020 label Biography information for George Freeman
tabling member	1538 label Biography information for Rosie Cooper

101579

registered interest
date	29/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pharmaceutical Price Regulation Scheme
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps he plans to take to ensure that the payments made by the pharmaceutical industry under the Pharmaceutical Price Regulation Scheme will be apportioned to each of the devolved health administrations, whilst securing that the mechanism in place for determining apportionment ensures that patients in all four constituent parts of the UK receive benefits from the payments made throughout the duration of the scheme.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	212420
answer	answer is ministerial correction date of answer 03/11/2014 answer text <p>The Government recognises that the Pharmaceutical Price Regulation Scheme (PPRS) payments that companies make under the 2014 scheme in respect of the United Kingdom need to be allocated to each of the devolved administrations in a fair way. Under the new arrangements introduced as part of the 2014 scheme, the apportionments will be agreed with the devolved administrations each year. The method for apportioning 2014-15 payments has not yet been finalised.</p><p> </p><p> </p><p> </p><p>It is a matter for the devolved health administrations to decide how to use the apportioned payments they receive from the PPRS.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 03/11/2014 17:36:17 answering member 4020 label Biography information for George Freeman
tabling member	1538 label Biography information for Rosie Cooper

101583

registered interest
date	29/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pharmaceutical Price Regulation Scheme
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, if he will make it his policy to use the Pharmaceutical Price Regulation Scheme to make the UK (a) a global leader in providing patients access to the most innovative appropriate medicines and (b) an attractive place for pharmaceutical companies to locate and invest.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	212419
answer	answer is ministerial correction date of answer 04/11/2014 answer text <p>The 2014 Pharmaceutical Price Regulation Scheme (PPRS) supports the National Health Service to improve patient access to clinically and cost effective medicines in a number of ways:</p><p> </p><p> </p><p> </p><p>- by making medicines more affordable. The PPRS limits growth in the vast majority of spend on branded medicines with industry making payments for spend above the agreed limit;</p><p> </p><p> </p><p> </p><p>- by providing stability and predictability to the Government and the pharmaceutical industry thereby promoting a strong and profitable pharmaceutical industry which encourages innovation and the development of high value treatments; and</p><p> </p><p> </p><p> </p><p>- by a number of agreed measure to improve access to branded medicines commensurate with the outcomes they offer patients.</p><p> </p><p> </p><p> </p><p>Sales of new products are exempt from PPRS payments though still included in the overall limit on growth and the payments made by industry as a whole. This creates a strong in-built incentive in the scheme for companies to innovate.</p><p> </p><p><br> In respect of England, the anticipated PPRS payments for 2014-15 were passed on to NHS England through the Mandate and as such were included within commissioner allocations. In addition, an indicative budget for NHS England for 2015-16 was set on the basis of, amongst other things, the PPRS payment forecast available in 2014. <br> <br> In accordance with normal Government accounting rules and the agreed PPRS, there is no separately identified or ring-fenced funding stream associated with PPRS payments. Nevertheless, the Government can provide an assurance that all PPRS payments received for England will be used for spending on improving patients’ health and care. As part of this, following discussion with the Department, NHS England and the Association of the British Pharmaceutical Industry are now pressing ahead with plans to improve access to and optimise the use of medicines to improve patient outcomes.</p><p> </p><p> </p><p> </p><p>More generally, the Government’s <em>Strategy for UK Life Sciences</em> sets out an ambitious long-term programme of action to improve the wider environment for pharmaceutical innovation and make the United Kingdom a world-leading place for life sciences investment. The Strategy has delivered £2 billion in industry and private sector investment in the United Kingdom since it was launched in December 2011.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 212417 212418 question first answered 04/11/2014 17:36:41 answering member 4020 label Biography information for George Freeman previous answer version 25832 answering member constituency Mid Norfolk answering member printed George Freeman answering member 4020 label Biography information for George Freeman
tabling member	1538 label Biography information for Rosie Cooper